$0
Updated Results from BioNTech’s BNT211; Triumvira’s TAC01-HER2 Clinical Safety and Efficacy Data; Dosing Levels of ICT’s GCC19CART; ESMO 2022 Presentations Analysis
ESMO 2022 Presentations Analysis: BioNTech, Triumvira, and ICT presented clinical updates from their novel cell therapies in solid tumors. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below: